Contact
Please use this form to send email to PR contact of this press release:
Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
TO:
Please use this form to send email to PR contact of this press release:
Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
TO: